



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Phage display technology for novel tumor- and vascular-targeted therapies against neuroblastoma

This is the author's mar	iuscript		
Original Citation:			
Availability:			
•	http://bdl.hondlo.not/2219/1605412	oines 2010 02 25T14:3	4.207
This version is available	http://hdl.handle.net/2318/1695413	since 2019-03-25T14:3	1.302
Terms of use:			
Open Access			
•	s the full text of works made available as "Op	en Access". Works made availat	ole under a
Creative Commons licens	se can be used according to the terms and co	nditions of said license. Use of	all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.			

(Article begins on next page)



Advertisement

Cancer Research

Search... Q

Advanced Search

Home

About

Articles

For Authors

Alerts

News

Experimental and Molecular Therapeutics

Phage display technology for novel tumor- and vascular-targeted therapies against neuroblastoma

Fabio Pastorino, Daniela Di Paolo, Monica Loi, Serena Marchio, Marco Soster, Renato Longhi, Angelo Corti, Theresa Allen, Federico Bussolino, Wadih Arap, Renata Pasqualini, and Mirco Ponzoni **DOI:** Published May 2008

Article


Info & Metrics

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

Abstract

4114

Disseminated neuroblastoma (NB), the most common extra-cranial solid tumor in children, is refractory to most current therapeutic regimens and hence the prognosis remains very poor. Conventional anticancer therapy with chemotherapeutic drugs has been a mainstay for several decades, but the poor selectivity of these agents causes severe dose-limiting side-effects and limits their clinical utility. We recently showed that the therapeutic index of anticancer drugs is increased by liposome encapsulation and further improvements of the intrinsic tumor selectivity of liposomes has been obtained by coupling tumor-specific antibodies and/or peptides to the surface of the lipidic envelop. In this direction, phage display technology, used as a powerful tool in the discovery of ligands specific to receptor on the surface of tumor and tumor endothelial cells, could impact clinical issues including functional diagnosis and cell-specific drug delivery. Moreover, the targeting of



therapeutics to tumor blood vessels, using probes that bind to specific molecular addresses in the vasculature, combines blood vessel destruction with the expected anti-tumor activities of the drug, resulting in increased efficacy and reduced toxicity. Tumor associated endothelial and perivascular cells either over-express angiogenic markers or express unique epitopes. Targeting cytotoxic antibodies or drugs to these molecular markers leads to destruction of the tumor vasculature and, indirectly, to tumor cell death. Recently, in vivo selection of phage display libraries was used to isolate peptides binding specifically to the tumor blood vessel addresses aminopeptidase N (APN) and A (APA). APN-targeted, doxorubicin (DXR)-entrapped, liposomes displayed enhanced anti-tumor effects and prolonged survival in NB-bearing mice. APA-targeted, liposomal DXR, alone and in combination with the APNtargeted formulation, are under investigation for their effectiveness on inducing tumor regression in clinically relevant animal models of human NB. In the meanwhile, we set up a protocol for the isolation of heterogeneous cell populations by tissue fractionation of primary tumor and metastases from orthotopic NB-bearing mice. We screened these tissues with phage-displayed peptide libraries, obtaining more than 60 single peptides binding to both tumor and tumor parenchyma cells, 10 of which are further validating. The availability of novel ligands binding to additional tumor-associated antigens, and to additional targets on both endothelial and perivascular tumor cells will allow to design more sophisticated liposomal targeted anticancer strategies that exhibit high levels of selective toxicity for the cancer cells. This would improve therapeutic outcome, decrease doselimiting side-effects and improve patient quality of life.

Footnotes

 99th AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

American Association for Cancer Research

Previous

▲ Back to top

Advertisement

No related articles found.

Google Scholar

- ▶ Cited By...
- ▶ More in this TOC Section

×